Rituximab in systemic sclerosis-associated interstitial lung disease: A systematic review and meta-analysis.

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a serious condition with limited treatment options.
• Conventional therapies for SSc-ILD may be suboptimal, necessitating exploration of alternative treatments.
• Corticosteroid use is often limited due to potential side effects.

Purpose of the Study:

• To evaluate the efficacy of rituximab in treating SSc-ILD.
• To compare rituximab's effects against conventional treatments for SSc-ILD.
• To investigate rituximab's benefits in patients with progressive SSc-ILD despite standard therapy.

Main Methods:

• A systematic review and meta-analysis of six studies (2 randomized, 4 non-randomized) involving adult SSc-ILD patients.
• Literature search conducted across Ovid MEDLINE, Cochrane Library, EMBASE, and KoreaMed.
• Primary outcome: change in forced vital capacity (FVC) to assess disease progression.

Main Results:

• Rituximab significantly reduced FVC decline in SSc-ILD patients compared to conventional treatment (SMD 0.65, P=.03).
• No significant differences were observed in lung diffusing capacity or modified Rodnan skin score.
• Rituximab demonstrated a lower incidence of leukopenia versus cyclophosphamide (P=.02) with a trend towards fewer infections.

Conclusions:

• Rituximab shows potential clinical benefit for SSc-ILD, particularly in cases progressing despite conventional therapy.
• Further research is warranted to confirm the clinical utility of rituximab in SSc-ILD management.
• Rituximab may offer a safer alternative regarding specific adverse events like leukopenia.